Immatics
Yahoo Finance • 4 hours ago
Mizuho reiterates Outperform rating on Immatics stock following Q2 results
Investing.com - Mizuho has reiterated an Outperform rating and $16.00 price target on Immatics (NASDAQ:IMTX) following the company’s second-quarter 2025 financial results reported last week. According to InvestingPro data, analyst targets... Full story
Yahoo Finance • 5 days ago
Immatics NV earnings missed by €0.28, revenue fell short of estimates
Investing.com - Immatics NV (NASDAQ: IMTX) reported second quarter EPS of €-0.58, €0.28 worse than the analyst estimate of €-0.30. Revenue for the quarter came in at €5.5M versus the consensus estimate of €13.37M. Immatics NV’s stock pr... Full story
Yahoo Finance • 5 days ago
Immatics Announces Second Quarter 2025 Financial Results and Business Update
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with metastatic melanoma in da... Full story
Yahoo Finance • last month
Here Is What You Need To Know Before Investing In Immatics N.V. (IMTX)
Immatics N.V. (NASDAQ:IMTX) is among the 13 Best German Stocks to Invest in Now. On May 31, the company shared results from the ongoing Phase 1b clinical trial evaluating the efficacy of IMA203 PRAME cell therapy in heavily pretreated pati... Full story
Yahoo Finance • 3 months ago
Immatics rises on data from early stage cell therapy trial
[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images I... Full story
Yahoo Finance • 4 months ago
Is Immatics (NASDAQ:IMTX) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Immatics (NASDAQ:IMTX) stands against other biotech penny stocks. Peter Marks’s depart... Full story
Yahoo Finance • 2 years ago
15 Small-Cap Stocks with High Potential
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stock... Full story
Yahoo Finance • 2 years ago
16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promising Long-Term Stocks According to Analyst... Full story
Yahoo Finance • 2 years ago
Levicept Appoints Eliot Forster as CEO
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology compan... Full story
Yahoo Finance • 2 years ago
Immatics Announces Third Quarter 2023 Financial Results and Business Update
ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR) not reached at median follow-up of 14.4 months including responses ongoing at >15 months after infusi... Full story
Yahoo Finance • 3 years ago
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has... Full story
Yahoo Finance • 3 years ago
10 Best Healthcare Stocks For the Long Term
In this article, we will take a look at the 10 best healthcare stocks for the long term. You can skip this part and go to 5 Best Healthcare Stocks For the Long Term. The healthcare sector is one of those rare, evergreen areas of the indus... Full story
Yahoo Finance • 3 years ago
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12) at or above target dose across Phase 1a and Phase 1b; confirmed responses seen across d... Full story
Yahoo Finance • 3 years ago
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
Immatics N.V. Patient enrollment for IMA401 Phase 1 trial started at first clinical site in Germany The study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid... Full story
